Compare GSK plc (GSK) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Redwire Corporation — how do they compare? GSK plc trades at $46.66 (market cap $91.88B), while Redwire Corporation trades at $9.59 (market cap $2.44B). The key difference: GSK plc is far larger — about 37.7× Redwire Corporation's market cap, and GSK plc pays a 3.9% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Redwire Corporation for 18 Days on average.
| GSK | RDW | |
|---|---|---|
Market Cap | $91.88B | $2.44B |
Volume | 7,730,529 | 11,053,212 |
Sector | Health | Industrials |
52-Week High | $61.18 | $25.90 |
52-Week Low | $43.24 | $5.06 |
Typical Hold Time | 93 Days | 18 Days |
Enterprise Value | $111.88B | $1.97B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Redwire Corporation (RDW) trades at $9.57, down 6.54% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported negative earnings with Q2 2026 EPS of -$0.19 missing expectations, though revenue growth remains strong at 89.6% year-over-year. Recent developments include a $980 million Space Force contract award and partnerships with Honda and Sophia Space for robotics and orbital data center technology.
Despite strong analyst support (80% buy ratings) and a $14.88 price target suggesting 55% upside, RDW faces significant fundamental challenges with negative profit margins and cash burn. The stock presents high-risk speculation on space infrastructure growth, dependent on successful execution and SpaceX's Starship development timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
